✦ LIBER ✦

Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome

✍ Scribed by Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Ohnishi; Reiji Haba

Book ID: 107618952
Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 216 KB
Volume: 91
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0500-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Restoration of cardiac function by an ir

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload

✍ Toru Kiguchi; Yoshikazu Ito; Yukihiko Kimura; Kazuma Ohyashiki 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 191 KB

Overview of guidelines on iron chelation

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

✍ Norbert Gattermann 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 175 KB

A safety, pharmacokinetic and pharmacody

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

✍ Keisuke Miyazawa; Kazuma Ohyashiki; Akio Urabe; Tomoko Hata; Shinji Nakao; Keiya 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 378 KB

Effect of androgen therapy and anemia on

Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes

✍ Piedras, Josefa; Hernández, Guadalupe; López-Karpovitch, Xavier 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 2 views

Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders.

Predicted costs of iron-chelators in mye

Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates

✍ Senthilkumar Durairaj; Stephen Chew; Ann Hyslop; Norene Keenan; Michael J. Grove 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 3 views

## Abstract Consideration of iron‐chelation (IC) in transfusion‐dependent patients is recommended in most clinical‐practice guidelines on myelodysplastic syndromes (MDS). The financial impact of IC on health‐care systems is predicted through economic modeling, but an analysis based on actual preval

Thromboelastogram showing an undesirable

Thromboelastogram showing an undesirable effect of platelet transfusion on blood coagulability and fibrinolysis in a patient with aplastic anemia

✍ Shinji Kohro; Michiaki Yamakage; Tomoko Takeda; Akiyoshi Namiki 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 283 KB